Compare Davita Inc (DVA) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs QUALCOMM, Inc. — how do they compare? Davita Inc trades at $178.35 (market cap $11.72B), while QUALCOMM, Inc. trades at $163.16 (market cap $170.28B). The key difference: QUALCOMM, Inc. is far larger — about 14.5× Davita Inc's market cap, and QUALCOMM, Inc. pays a 2.27% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | QCOM | |
|---|---|---|
Market Cap | $11.72B | $170.28B |
Sector | Health | Technology |
52-Week High | $240.96 | $251.10 |
52-Week Low | $103.87 | $124.07 |
Enterprise Value | $24.44B | $177.24B |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Qualcomm (QCOM) trades at $167.86, up 4.66% with strong recent earnings performance despite a Q2 2026 miss. The stock shows bullish technical signals with solid fundamentals including $44.28B revenue and 21.01% net margin. Recent news highlights Qualcomm's AI and automotive diversification efforts, though competition from Nvidia's PC chip entry poses challenges. Analyst consensus targets $200.56 with 42.65% buy ratings.
Qualcomm presents a balanced opportunity with strong cash flow generation and strategic diversification into AI/data centers offsetting smartphone market softness. Key risks include margin pressures and intensified competition. The current valuation at 19.18 P/E appears reasonable given growth initiatives, supporting a cautiously optimistic outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
